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Abstract: Aberrant expression of Cancer Osaka Thyroid Oncogene
mitogen-activated protein kinase kinase kinase 8 (COT) (MAP3K8) is a
driver of resistance to B-RAF inhibition. However, the de novo expres-
sion and clinical implications of COT in papillary thyroid cancer (PTC)
have not been investigated.
The aim of this study is to investigate the expression of A-, B-, C-
RAF, and COT in PTC (n¼ 167) and analyze the clinical implications of
aberrant expression of these genes.
Quantitative polymerase chain reaction (qPCR) and immunohisto-
chemical staining (IHC) were performed on primary thyroid cancers.
Expression of COT was compared with clinicopathological character-
istics including recurrence-free survival. Datasets from public reposi-
tory (NCBI) were subjected to Gene Set Enrichment Analysis (GSEA).
qPCR data showed that the relative mRNA expression of A-, B-,
C-RAF andCOT of PTCwere higher than normal tissues (allP< 0.01). In
addition, the expression of COT mRNA in PTC showed positive corre-
lation with A- (r¼ 0.4083, P< 0.001), B- (r¼ 0.2773, P¼ 0.0003), and
C-RAF (r¼ 0.5954, P< 0.001). The mRNA expressions of A-, B,- and
C-RAF were also correlated with each other (all P< 0.001). In IHC, the
staining intensities ofB-RAF andCOTwere higher in PTC than in normal
tissue (P< 0.001). Interestingly, moderate-to-strong staining intensities
of B-RAF and COT were more frequent in B-RAFV600E-positive PTC
(P< 0.001, P¼ 0.013, respectively). In addition, aberrant expression of
COT was related to old age at initial diagnosis (P¼ 0.045) and higher
recurrence rate (P¼ 0.025). In multivariate analysis, tumor recurrence
was persistently associated withmoderate-to-strong staining of COT after
adjusting for age, sex, extrathyroidal extension, multifocality, T-stage, N-Shin, MD, Eun Jig ,
and Young Suk Jo, MD, PhD
free survival (mean follow-up duration, 14.2 4.1 years; P¼ 0.0403).
GSEA indicated that gene sets related to B-RAF-RAS (P< 0.0001,
false discovery rate [FDR] q-value¼ 0.000) and thyroid differentiation
(P¼ 0.048, FDR q-value¼ 0.05) scores were enriched in lower
COT expression group and gene sets such as T-cell receptor signaling
pathway and Toll-like receptor signaling pathway are coordinately upre-
gulated in higher COT expression group (both, P< 0.0001, FDR
q-value¼ 0.000).
Aberrant expression of A-, B-, and C-RAF, and COT is frequent in
PTC; increased expression of COT is correlated with recurrence of PTC.
(Medicine 94(6):e548)
Abbreviations: A-RAF = v-raf murine sarcoma 3611 viral
oncogene homolog, B-RAF = v-raf murine sarcoma viral
oncogene homolog B, BRS = B-RAF-RAS score, COT = Cancer
Osaka Thyroid Oncogene mitogen-activated protein kinase kinase
kinase 8, C-RAF = v-raf-1 murine leukemia viral oncogene
homolog 1, CXCL10 = chemokine (C-X-C motif) ligand 10,
CXCL11 = chemokine (C-X-C motif) ligand 11, ERK =
extracellular signal-regulated kinase, FDG PET/CT = 18-Fluoro-
deoxyglucose positron emission tomography, FDR = false
discovery rate, GAPDH = glyceraldehyde-3-phosphate
dehydrogenase, GSEA = gene set enrichment analysis, IFNG =
gamma interferon, IHC = immunohistochemical staining, IL-1 =
interleukin-1, LCK = lymphocyte-specific protein tyrosine kinase,
MAPK = mitogen-activated protein kinase, MEK = mitogen-
activated protein kinase kinase, PI3K = phosphatidylinositol-3-OH
kinase, Pin1 = PeptidylprolylCis/Trans Isomerase NIMA-
Interacting 1, PTC = papillary thyroid cancer, PTEN =
phosphatase and tensin homolog, RAI = radioactive-iodine,
STAT3 = Signal transducer and activator of transcription 3, TDS
= thyroid differentiation score (TDS), THW = thyroid hormone
withdrawal, THW = thyroid hormone withdrawal, TLR7 = toll-like
receptor 7, TLR8 = toll-like receptor 8, TNF = tumor necrosis
factor, WBS = whole body scan.
INTRODUCTION
P atients with papillary thyroid cancer (PTC) generally have arelatively indolent clinical course and favorable therapeutic
outcomes,1 although persistent or recurrent PTC occurs in 10%
to 15% of cases.2 Management of persistent or recurrent PTC
consists of surgical resection followed by radioactive-iodine
(RAI) therapy.3,4 However, a significant proportion of persist-
ent or recurrent PTC is not amenable to surgical resection and
shows RAI refractoriness.4
The RAS-RAF-mitogen-activated protein kinase (MAPK)
best characterized signal pathways to
m a receptor on the cell surface to the
this conserved signaling pathway, RAF
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proteins such as A-, B-, and C-RAF are activated by RAS and
then lead to activation of the dual-specific protein kinases
MEK1/2 (mitogen-activated protein kinase kinase, MAPK
kinase) and subsequently ERK1/2 (extracellular signal-
regulated kinase, ERK, MAPK).5 Although all 3 RAF proteins
regulate ERK signal pathway, the individual RAF isoforms can
be differentially regulated in cell type-specific or context-
dependent manner.6–8 In addition, the RAF is forms have
strikingly different phosphorylation sites.5 Recently, A-RAF
has been reported to act as a scaffold to stabilize B-RAF:C-RAF
heterodimers, whereas A-RAF dimerization also promotes
MAPK activation.9,10 Besides 3 RAF is forms, Cancer Osaka
Thyroid Oncogene mitogen-activated protein kinase kinase
kinase 8 (COT) (MAP3K8), a serine/threonine kinase, was
shown to play a role in the MAPK activation.11 To explain
the regulatory mechanism of MAPK activation by COT, it has
been suggested that COT is able to phosphorylate MEK-1.12
In fact, PTC is the result of the abnormal activation of
RAS-RAF-MAPK signal pathway induced by RET/PTC re-
arrangement, Ras mutations, or B-RAFV600E mutation.4 Fol-
lowing the discovery that the B-RAFV600E mutation is present in
a high proportion of many human cancers,13 several novel
targeted agents were developed for B-RAFV600E-positive can-
cers.14 Because the incidence of the B-RAFV600E mutation in
PTC is high (40%–80%), these new agents were considered
promising therapeutic modalities.15,16 Preclinical studies indi-
cated the dependency of B-RAFV600E tumors on MAPK signal-
ing cascade, whereas the efficacy of both RAF and MEK
inhibitors has been demonstrated in several clinical trials.17–
19 However, de novo and acquired resistance to these agents has
since emerged as a new therapeutic obstacle.20,21
Mechanisms of resistance to RAF inhibitors can be divided
into two categories according to the dependency on RAF dimer-
ization.22,23 In the first category, mutations in NRAS such as
NRASQ61, the p61BRAFV600E splice variant, and C-RAF over-
expression are involved in amechanism that is dependent onRAF
dimerization. The p61B-RAFV600E splice variants lacking the
RAS-binding domain can dimerize in a RAS-independent man-
ner and generateMEK-ERK signal propagation. NRASmutation
and increased expression of C-RAF can also increase RAF
dimerization which is insensitive to RAF inhibitor.24–26 In the
second category, aberrant expression of COT or MEK mutation
functions independently of RAF dimerization.11 Based on a
functional genomic approach, COT can generate resistance to
RAF inhibitors by MEK dependent mechanisms.11,23 While the
newer targeted agents are often administered to patients with
persistent or recurrent PTC,27 the incidence of de novo or
acquired drug resistance in these patients has not been determined
with certainty. Nonetheless, the outcomes in patients with PTC
following administration of RAF (Sorafenib) or MEK inhibitor
(Selumetinib, AZD6244, ARRY-142886) are generally poor
compared with other cancers such as melanoma.28–30
In this study, we investigated the expression status ofA-, B-,
C-RAF, and COT mRNA in PTC with respect to that in matched
normal thyroid tissues and analyzed the relationship between
COT expression and that of RAF paralogues to investigate the
presence of de novo drug resistance mechanisms and understand
the clinical implications of aberrant expression of these genes.
METHODS
Lee et alSubjects and Clinical Data
This study enrolled 167 patients (34 male and 133 female)
undergoing total thyroidectomy with or without neck node
2 | www.md-journal.comdissection followed by radioactive iodine ablation for manage-
ment of classical PTC from January 1987 to December 2002 at
Severance Hospital, Seoul, South Korea. The study subjects
showed no visible remnant in the first Diagnostic 131I whole
body scan (WBS) with following thyroid hormone withdrawal
(THW) performed 6 to 12 months after remnant ablation. The
sample size was calculated by Web-based Sample Size/Power
Calculations (http://www.stat.ubc.ca). Patient information and
clinicopathological parameters were analyzed retrospectively;
the overall median follow-up time was 14.2 4.1 years. During
this time, recurrence was diagnosed by: histopathologic diag-
nosis of clinically suspicious lymph node identified by neck
ultrasound or physical examination (n¼ 23, 82.1%); newly
detected lesion in 131I diagnostic WBS, 18-Fluoro-deoxyglu-
cose positron emission tomography (FDG PET/CT) or chest
computed tomography (CT) (n¼ 5, 17.9%) performed due to
patient’s serum thyroglobulin 2mg/L with gradual increase
following THW. Tissue samples were taken from the central
area of the tumor and from contralateral histologically normal
tissue. On histological examination, cellularity was>90% in all
primary PTCs. All protocols were approved by the institutional
review board of Severance Hospital.
RNA Isolation and Real-rime PCR
Total RNAwas extracted using Trizol reagent (Invitrogen,
Carlsbad, CA, USA), and complementary DNA (cDNA) was
prepared from total RNA using M-MLV reverse transcriptase
(Invitrogen) and oligo-dT primers (Promega, Madison, WI,
USA). Quantative RT-PCR (qRT-PCR) was performed on
cDNA using the QuantiTect SYBR Green RT-PCR Kit (Qiagen,
Valencia, CA, USA) with the following primers: A-RAF, 50-
CCT GGC GTT CTG TGA CTT CTG-30 and 50-CGG TTG
GTA CTC ATG TCA ACA C-30; B-RAF, 50-GTG GAT GGC
ACC AGA AGT CA-30 and 50-AGG TAT CCT CGT CCC ACC
AT-30; C-RAF, 50-GGGAGCTTGGAAGACGATCAG-30 and
50-ACACGGATAGTGTTGCTTGTC-30; COT, 50-ATGGAG
TACATGAGCACTGGA-30 and 50-GCTGGCTCTTCACTT
GCA TAA AG-30; interferon, gamma (IFNG), 50-TCG GTA
ACT GAC TTG AAT GTC CA-30 and 50-TCG CTT CCC TGT
TTTAGC TGC-30; lymphocyte-specific protein tyrosine kinase
(LCK), 50-TCT GCA CAG CTATGA GCC CT-30 and 50-GAA
GGAGCC GTG AGT GTT CC-30; CD247, 50-GGC ACAGTT
GCCGATTACAGA-30 and 50-CTGCTGAACTTCACTCTC
AGG-30; chemokine (C-X-C motif) ligand 10 (CXCL10), 50-
GTG GCA TTC AAG GAG TAC CTC-30 and 50-TGA TGG
CCT TCG ATT CTG GAT T-30; chemokine (C-X-C motif)
ligand 11 (CXCL11), 50-GAC GCT GTC TTT GCATAGGC-30
and 50-GGA TTT AGG CAT CGT TGT CCT TT-30; toll-like
receptor 7 (TLR7), 50-CAC ATA CCA GAC ATC TCC CCA-30
and 50-CCC AGT GGA ATA GGT ACA CAG TT-30; toll-like
receptor 8 (TLR8), 50-GAC TACAGGAAGTTCCCCAAAC-
30 and 50-ATA CCG GGA TTT CCG TTC TGG-30; glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH), 50-GGA GCG
AGATCC CTC CAAAAT-30 and 50-GGC TGT TGT CATACT
TCT CAT GG-30. qRT-PCR experiments were repeated 3 times,
and each experiment was performed in triplicate.
DNA Isolation and Dideoxysequencing
Genomic DNA from formalin-fixed, paraffin-embedded
tissue specimens was prepared from five 10-mm sections after
Medicine  Volume 94, Number 6, February 2015microdissection. In the case of cancers, paraffin-embedded
thyroid tissue specimens had >90% tumor cells. Genomic
DNA was isolated using the EZ1 DNA Tissue Kit (Qiagen,
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
Chatsworth, CA, USA). Exon 15 of the BRAF gene was
amplified by PCR using standard conditions (958C 5min;
948C 30 s, 588C 30 s,728C 30 s, for 32 cycles;
708C 10min) and the following primers: forward 50-ATG
CTT GCT CTG ATA GGA AA-30 and reverse 50-ATT TTT
GTG AAT ACT GGG GAA-30. The amplified products were
purified with the MinElute PCR Purification Kit (Qiagen) and
were then sequenced on an ABI PRISM 3730XL automated
capillary DNA Sequencer using the BigDye Terminator Cycle
Sequencing Ready Reaction Kit (Applied Biosystems, Foster
City, CA, USA).
Western Blot Analysis and Immunohistochemical
Staining
Western blot analysis was performed according to standard
methods with commercially available antibodies: A-RAF rabbit
polyclonal antibody (#4432, Cell Signaling, Danvers, MA,
USA), B-RAF rabbit polyclonal antibody (sc-9002, Santa Cruz
Biotechnology, Inc., Dallas, Texas, USA), C-RAF rabbit poly-
clonal antibody (#9422, Cell Signaling, USA) and COT rabbit
polyclonal antibody (sc-720, Santa Cruz Biotechnology) and
anti-b-Actin Antibody (#4967, Cell Signaling). Immunohisto-
chemical staining (IHC) for B-RAF and COTwas performed in
Medicine  Volume 94, Number 6, February 2015167 cases of PTC and matched normal tissues. Briefly, 4-mm
tissue sections were heated at 608C, deparaffinized in xylene,
and hydrated in a graded series of alcohol. Antigen retrieval was
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FIGURE 1. Comparison of relative mRNA expression ratio (PTC/matc
B-RAF (B), C-RAF (C), and COT (D). Relative expression was calculated
Foster City, CA, USA). 2DCtn¼2CtGAPDH-Cttarget calculation was used fo
was calculated by relative mRNA expression value of PTC/that of match
with the paired t test. Data are average mean values.

P<0.01,

P
analysis to compare protein expression between PTC andmatched nor
and each experiment was performed in triplicate. COT¼Cancer Osaka
8, PTC¼papillary thyroid cancer.
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.performed bymicrowaving in citrate buffer for 10min. Endogen-
ous peroxidase activity was inactivated by incubation in 3%
hydrogen peroxide for 10min. Nonspecific binding sites were
blocked by incubating in 10% normal goat serum diluted with
phosphate-buffered saline. Tissue sections were then incubated
with primary antibodies: B-RAF (sc-9002) or COT rabbit poly-
clonal antibody (sc-720) for 60min at room temperature. All
sections were sequentially treated with biotinylated anti-rabbit
immunoglobulin for 30min, peroxidase-labeled streptavidin for
30min, and diaminobenzidine in the presence of hydrogen
peroxide. Controls were incubated with PBS in place of primary
antibody, and no positive staining was observed in any case. In
addition to negative controls, sections of human fallopian tube
tissues were used as a positive control for B-RAF and human
small intestine tissues as a positive control for COT. Staining was
scored as follows: 1, no staining; 2, weak or focal staining; 3,
moderate staining in most cells; and 4, strong staining in most
cells. To support our IHC-P (Immunohistochemistry-Paraffin
Embedded Tissues) data, we reviewed the representative images
of IHC-P for A-, B-, C-RAF and COT fromHuman Protein Atlas
program (http://www.proteinatlas.org/).
Gene Set Enrichment Analysis of COT-Correlated
COT as a Recurrence Predictor of PTCGenes
Microarray data from the Gene Expression Omnibus
(GEO) of NCBI (Data Set Record GSE33630) were subjected
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<0.001. All P values are 2-sided. (E) Representative western blot
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to gene set enrichment analysis (GSEA).31 Genes strongly
correlated to COTwere verified by qRT-PCR using cDNA from
our subjects.
Statistical Analysis
Statistical analysis was carried out using either SPSS
version 18.0 for Windows (IBM Corporation, Armonk, NY,
USA) or GraphPad Prism (GraphPad Software, Inc, San Diego,
CA, USA). Data are presented as the mean standard deviation.
All P values are 2-sided.
RESULTS
Increased Expression of A-, B-, C-RAF and COT
mRNA in PTC
To investigate the expression of A-, B-, C-RAF, and COT
in PTC, we first performed qPCR using mRNA derived from
primary PTC and contralateral matched normal thyroid tissues.
Excluding 32 cases presenting poor isolated mRNA quality, we
conducted mean comparisons using a paired t-test (n¼ 135). As
shown in Figure 1 A–D, the relative mRNA expression of A-,
B-, C-RAF and COT were higher than normal tissues. Support-
ing our qPCR data, western blot analysis showed that A-, B-, C-
RAF and COT expressions were increased in PTC compared
with matched normal tissues (Figure 1E). Furthermore, expres-
sion of COT mRNA significantly correlated with that of
A- (r¼ 0.4083, P< 0.001), B- (r¼ 0.2773, P¼ 0.0003), and
C-RAF (r¼ 0.5954, P< 0.001) (Figure 2A–C. The mRNA
expression of A-, B-, and C-RAF correlated with each other
(Figure 2D–F). Interestingly, the mRNA expressions of A-, B-,
Lee et alC-RAF and COT were higher in BRAFV600E-positive PTC
compared with BRAFV600E-negative PTC (Supplementary
Fig. 1, http://links.lww.com/MD/A207).
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To validate our qPCR data and western blot analysis, IHC
was performed using formalin-fixed, paraffin-embedded thyr-
oid tissue blocks (number of tumor samples¼ 167). In fact, we
tried to perform IHC-P for A-, B-, C-RAF and COT. However,
because we could observe no staining intensity of A-RAF and
focal or weak nuclear staining intensities of C-RAF (as pre-
sented in Human Protein Atlas, Supplementary Fig. 2, http://
links.lww.com/MD/A207), we analyzed the results of IHC-P
data for B-RAF and COT. Twenty-four cases out of 28 normal
thyroid tissues showed only focal staining for B-RAF and
remaining 4 cases showed moderate staining, although PTC
showed moderate-to-strong staining intensities (Figure 3A and
B). PTC showed significantly higher staining of B-RAF com-
pared with normal thyroid tissues (P< 0.001, Figure 3C). Inter-
estingly, expression of B-RAF was more frequently detected in
B-RAFV600E-positive PTC (P< 0.001, Figure 3D). However,
statistical analysis to investigate the correlation of B-RAF
expression status with clinicopathological parameters did not
show any significant implication of B-RAF expression on
clinical parameters such as Kaplan–Meier analysis of recur-
rence-free survival (Figure 3E). In the case of COT, 26 cases out
of 28 normal thyroid tissues did not show any staining intensity
(Figure 4A, upper panel) whereas remaining 2 cases presented
moderate staining intensity (Figure 4A, lower panel). Interest-
ingly, these 2 cases of normal thyroid tissues with moderate
COT staining showed lymphocytic infiltration around thyroid
follicles (arrows). Although PTC showed various staining
intensities of COT that ranged from no staining to strong
staining (Figure 4A and B), our analysis of group comparison
indicated that PTC showed significantly higher staining of COT
Medicine  Volume 94, Number 6, February 2015compared with normal thyroid tissues (P< 0.001, Figure 4C).
Interestingly, aberrant expression of COT was more frequently
detected in B-RAFV600E-positive PTC (P¼ 0.013, Figure 4D).
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FIGURE 3. Relation of B-RAF expression with B-RAFV600E mutation and recurrence-free survival. (A) Representative image of IHC-P using
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Based on IHC data that indicated higher expression of
COT in PTC, statistical analyses were performed to investigate
possible correlations with clinicopathological parameters. Inter-
estingly, aberrant expression of COT (moderate-to-strong stain-
ing) was related to old age at initial diagnosis (P¼ 0.045,
Table 1) and higher prevalence of B-RAFV600E mutation
(P¼ 0.023). Moreover, the recurrence rate of PTC was signifi-
cantly higher in PTC showing moderate-to-strong staining
(P¼ 0.025). In multivariate analysis, tumor recurrence was
associated with moderate-to-strong staining of COT after
adjusting for age, sex, extrathyroidal extension, multifocality,
T-stage, N-stage, TNM, and B-RAFV600E mutation (odds ratio
[OR] 4.662; 95% confidence interval [CI] 1.066–21.609;
P¼ 0.045, Table 2). Furthermore, Kaplan–Meier analysis
revealed that moderate-to-strong COT expression in PTC
was associated with shorter recurrence-free survival (mean
follow-up duration; 14.2 4.1 years, P¼ 0.0403, Figure 4E),
strongly suggesting that aberrant expression of COT is associ-
ated with recurrence of PTC.
COT-correlated Genes Indicated by GSEA
To get further insight into the molecular biological effects
of COT expression, we decided to perform GSEA using data
from a public repository, NCBI GEO (GSE33630, total 49 PTC
samples). Recently, integrated genomic characterization of PTC
recurrence-free survival according to BRAF expression. Group 1 ind
indicates strong staining intensity. IHC¼ immunohistochemical stsuggested that B-RAF-RAS score (BRS) and differentiation
score (TDS) can be useful to classify PTC into molecular
subtypes.32 Using this scoring system, BRAFV600E-positive
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.PTC indicated low BRS and TDS. In line with these findings,
when we performed GSEA on the PTC samples with the lowest
COT expression (n¼ 15) and those with the highest COT
expression (n¼ 15), we observed the gene sets related to
BRS and TDS were coordinately enriched in the lowest COT
expression PTCs (Figure 5A and B). In fact, COT has also an
important role to activate IKaB kinases, producing nuclear
factor-kB.33 Furthermore, COT promotes the tumor necrosis
factor (TNF)a and interleukin (IL)-2 production for T-lympho-
cyte activation.34,35 Supporting to this previous reports, in our
GSEA (Table 3), the top 20 KEGG gene sets enriched in the
highest COT expression PTCs included T-cell receptor signal-
ing pathway (P< 0.0001, false discovery rate [FDR] q
value¼ 0.000, Figure 5C) and Toll-like receptor signaling
pathway (P< 0.0001, FDR q value¼ 0.000, Figure 5D) verified
by qPCR using cDNA from our study subjects (Figure 5E).
Taken together, our GSEA data suggested that COT might have
multifaceted functions in cell proliferation and inflammatory
events of thyroid carcinogenesis.
DISCUSSION
Following the discovery of B-RAFV600E mutation as an
oncogenic kinase in various cancers including melanoma,
thyroid, lung, and cholangiocarcinoma, targeted agents against
B-RAFV600E kinase have taken a central role in cancer therapy.
es patients with PTC showing moderate staining of BRAF; Group 2,
ng, PTC¼papillary thyroid cancer.In this regard, sorafenib has activity against B-RAFV600E and is
licensed to treat RAI-refractory PTC.27 In addition, other RAF
inhibitors such as SB590885, encorafenib, dabrafenib, and
www.md-journal.com | 5
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of COTexpression between normal thyroid tissues and PTC. (D) COTexpression status according to the absence or presence of B-RAFV600E
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Lee et al Medicine  Volume 94, Number 6, February 2015vemurafenib are potential therapeutic anticancer agents with
clinical utility.36–39
In contrast to the high response rate of metastatic mela-
nomas to B-RAF inhibitors, RAF or MEK inhibitors show
limited efficacy in RAI-refractory thyroid cancer and thyroid
cancer cell lines harboring B-RAFV600E.28,29,40 One of the
possible explanations for the poor response to B-RAF inhibitors
in thyroid cancer is related to feedback-induced ligand-depen-
dent activation of HER2/HER3 signaling.29 In fact, recent
biological and clinical studies have revealed multiple mechan-
isms of drug resistance: elevated expression of C-RAF, COT1,
or mutant BRAF kinases; activating mutations in N-RAS,
MEK1, or AKT1; aberrant splicing of BRAF (p61BRAF);
activation of phosphatidylinositol-3-OH kinase (PI3K) by phos-
phatase and tensin homolog (PTEN) loss; and activation of
receptor tyrosine kinases, including platelet-derived growth
factor receptor, beta polypeptide, insulin-like growth factor 1
receptor, and epidermal growth factor receptor. Interactions
between tumors and their microenvironment are also related to
innate drug resistance to B-RAF inhibitors.29
mutation. IHC staining was scored as described in the Methods
association. (E) Kaplan–Meier estimates of recurrence-free surviva
showing no staining or focal staining of COT; Group 2, indicates
Oncogene mitogen-activated protein kinase kinase kinase 8, IHCIn this study, qPCR was performed to estimate the expres-
sion of A-, B-, C-RAF, and COT mRNAs. Interestingly,
expression of the 3 RAF paralogues and COT were all increased
6 | www.md-journal.comin PTC. Supporting this observation, our western blot analysis
indicated that the protein expressions of A-, B-, C-RAF, and
COT were increased in PTC. Unfortunately, IHC-P using
commercially available anti-A-RAF and anti-C-RAF antibodies
did not generate reliable data in our hands. The IHC-P for A-
RAF did not show any staining intensity and the IHC-P for C-
RAF presented nuclear staining, which implicated nonspecific
staining because CRAF is a kind of cytosolic proteins. How-
ever, our IHC data clearly demonstrated overexpression or
aberrant expression of BRAF and/or COT in PTC compared
with normal thyroid tissues. In line with our data, inspection of
transcriptome profiles indicates that COT expression is
increased in certain malignancies compared with normal tissues
(http://www.oncomine.org).35 Furthermore, the expression of
COT showed a strong positive correlation with RAF paralogues,
suggesting that this de novo drug resistance mechanism is
coordinately regulated in PTC. Taken together, we postulated
that de novo drug resistance mechanisms to RAF inhibitors
might be active in a significant proportion of PTC with expres-
sion of COT.
¼167). Group comparisons were performed by linear-by-linear
cording to COT expression. Group 1 indicates patients with PTC
derate to strong staining intensity. COT¼Cancer Osaka Thyroid
munohistochemical staining, PTC¼papillary thyroid cancer.In IHC-P using anti-BRAF antibody, we could observe
focal or moderate staining intensities in normal thyroid tissues
suggesting that B-RAF might be required in normal follicular
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 1. Clinicopathological Characteristics According to COT Expression Status
Patients with No/Focal Staining Patients With Moderate-to-strong Staining P Value
N¼ 37 (%) N¼ 130 (%)
Age, y 37.6 14.6 43.0 12.8 0.045
Sex (male:female) 8 (21.6):29 (78.4) 26 (20.0):104 (80.0) 0.829y
Tumor staging (T)
T1 6 (16.2) 24 (18.5) 0.416z
T2 7 (18.9) 32 (24.6)
T3 22 (59.5) 70 (53.8)
T4 2 (5.4) 4 (3.1)
Tumor Size (cm) 2.33 1.14 2.44 1.05 0.581
Extrathyroidal extension
Negative 11 (29.7) 61 (46.9) 0.164y
Minimal 24 (64.9) 60 (46.2)
Extensive 2 (5.4) 9 (6.9)
Multifocality
Negative 23 (62.2) 98 (75.4) 0.112y
Positive 14 (37.8) 32 (24.6)
Nodal metastasis
Negative 16 (43.2) 62 (47.7) 0.524z
N1a 17 (45.9) 58 (44.6)
N1b 4 (10.8) 10 (7.7)
TNM stage
I 23 (62.2) 81 (62.3) 0.63z
II 1 (2.7) 2 (1.5)
III 11(29.7) 34 (26.2)
IV 2 (5.4) 13 (10)
BRAFV600E mutation
Negative 9 (24.3) 13 (10) 0.023y
Positive 28 (75.7) 117 (90)
Recurrence
No 35 (94.6) 104 (80) 0.025y
Yes 2 (5.4) 26 (20)
COT¼Cancer Osaka Thyroid Oncogene mitogen-activated protein kinase kinase kinase 8.
re c
2 te
by
Medicine  Volume 94, Number 6, February 2015 COT as a Recurrence Predictor of PTCproliferation. In the case of COT, we could observe moderate
staining intensity in 2 cases of normal thyroid tissue derived
from patients showing high titer of anti-TPO antibody. In these
2 cases, we could also observe lymphocytic infiltration around
thyroid follicles. Taken together, we postulated that COT
expression might also play a role in inflammatory process such
as autoimmune thyroid disease.41,42
The other interesting finding is that the B-RAFV600E
mutation is related to higher B-RAF or COT expression in
PTC. This observation is clinically important because metastatic
PTC harboring B-RAFV600E presents RAI nonavidity and sup-
pression of B-RAF/MEK/MAPK pathway is able to restore
thyroid specific gene expression for effective RAI therapy.43,44
However, in line with our finding, there is a possibility that RAI-
refractory PTC harboring B-RAFV600E mutation with increased
BRAF and COT expression might present primary drug failure
using Sorafenib, which means de novo drug resistance.
Finally, we investigated potential correlations of B-RAF
and COT expression with clinicopathological parameters. In the

Data are presented as means standard deviation and P values we
yP values were calculated by pair-wise comparisons using Pearson x
zP values were calculated by comparisons of 3 or 4 groups in linearanalysis of B-RAF, we could not find any clinicopathological
significance. However, because all PTCs showed moderate-to-
strong staining intensities in our experiments, we concluded that
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.such kind of analysis is not suitable in this situation. Interest-
ingly, aberrant COT expression has significant impacts on
clinicopathological parameters. Higher age at initial diagnosis
was correlated with higher COT expression, and importantly
higher COT expression was also related to recurrence of PTC.
This indicates that COT is related not only to de novo drug
resistance, but also to tumor aggressiveness. In fact, we could
postulate that COT activates ERK primarily through MEK-
dependent mechanisms, resulting in increased ERK-dependent
transcriptional output without RAF signaling.11,45–47 However,
COT has an important function in the signal activator of pro-
inflammatory pathways in promoting cancer-associated inflam-
mation of tumor environment.48,49 For example, COT has a
pivotal role in TNF, IL-1, CD40, Toll-like receptor, and G
protein-coupled receptor-mediated MAPK signaling, although
the full understanding of the biochemical mechanism that lead
to the activation of COT still remains to be elucidated.35,50
Supporting this finding, our GSEA indicated that high COT
expression in PTC was related to immune-related KEGG gene
alculated by an independent samples t test.
st or Fisher exact test.
linear associations.sets. In addition, enhanced nuclear expression of Signal trans-
ducer and activator of transcription 3 (STAT3) was observed in
c-erbB-2 negative breast cancer with COT overexpression.51
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FIGURE 5. Relationship between expression levels of COT and gene sets. (A) B-RAF-RAS score, (B) thyroid differentiation score, (C) T-cell
receptor signaling pathway, (D) Toll-like receptor signaling pathway. Gene set enrichment analysis using gene-expression profiles selected
from NCBI GEO Record GSE33630. See detailed description in Methods and Results sections. (E) Quantitative PCR analysis of
representative mRNA expression in highest COT expression PTCs (red box, n¼7) and lowest COT expression PTCs (blue box, n¼7)
from our study subjects. Means were compared and analyzed by Mann–Whitney U test. All data are means standard error mean.
P<0.05,

P<0.01,

P<0.001. AllP values are 2-sided. All experiments were repeated 3 times, and each experiment was performed
in triplicate. COT¼Cancer Osaka Thyroid Oncogene mitogen-activated protein kinase kinase kinase 8, IHC¼ immunohistochemical
staining, PTC¼papillary thyroid cancer.
TABLE 2. Multivariate Analysis of the Association of Tumor Recurrence With COT Expression Levels
Tumor Recurrence
Odds Ratio 95% CI P Value
Moderate-to-strong staining

4.619 1.037–20.584 0.045
Moderate-to-strong stainingy 4.601 1.031–20.524 0.045
Moderate-to-strong stainingz 4.636 1.013–21.217 0.048
Moderate-to-strong staining§ 4.808 1.038–22.280 0.045
Moderate-to-strong stainingk 4.81 1.042–22.206 0.044
Moderate-to-strong staining 4.662 1.006–21.609 0.049
CI¼ confidence interval, COT¼Cancer Osaka Thyroid Oncogene mitogen-activated protein kinase kinase kinase 8.
Adjusted for age.
yAdjusted for age and sex.
z In addition to adjustmentb, adjusted for T stage and extrathyroidal extension.
§ In addition to adjustmentc, adjusted for multifocality and N stage.
k In addition to adjustmentd, adjusted for TNM stage.
 In addition to adjustmente, adjusted for B-RAFV600E mutation.
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TABLE 3. Top 20 KEGG Gene Sets Enriched in Highest COT Expression Group From GSE336300
Gene sets Size ES NOM P-val FDR q-val
1 KEGG_HEMATOPOIETIC_CELL_LINEAGE 35 0.80878 0 0
2 KEGG_INTESTINAL_IMMUNE_NETWORK_FOR_IGA_PRODUCTION 83 0.84463 0 0
3 KEGG_PRIMARY_IMMUNODEFICIENCY 45 0.89415 0 0
4 KEGG_TYPE_I_DIABETES_MELLITUS 62 0.8515 0 0
5 KEGG_LEISHMANIA_INFECTION 37 0.81087 0 0
6 KEGG_GRAFT_VERSUS_HOST_DISEASE 40 0.85964 0 0
7 KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 34 0.71003 0 0
8 KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION 245 0.74535 0 0
9 KEGG_ALLOGRAFT_REJECTION 107 0.84805 0 0
10 KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY 173 0.72214 0 0
11 KEGG_CHEMOKINE_SIGNALING_PATHWAY 71 0.70704 0 0
12 KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 81 0.72756 0 0
13 KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY 98 0.70105 0 0
14 KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS 49 0.69997 0 0
15 KEGG_B_CELL_RECEPTOR_SIGNALING_PATHWAY 129 0.73116 0 0
16 KEGG_AUTOIMMUNE_THYROID_DISEASE 107 0.75245 0 0
17 KEGG_NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 27 0.74287 0 0
18 KEGG_ASTHMA 51 0.81737 0 0
19 KEGG_CELL_ADHESION_MOLECULES_CAMS 87 0.66117 0 5.47E-05
20 KEGG_VIRAL_MYOCARDITIS 125 0.6746 0 2.10E-04
inas
Medicine  Volume 94, Number 6, February 2015 COT as a Recurrence Predictor of PTCThe other possible mechanism of COT to affect tumor aggres-
siveness is the active phosphorylation of Pin1 (Peptidylprolyl-
Cis/Transisomerase, NIMA-interacting 1) by COT, increasing
cyclin D1 abundance.52
In this study, we evaluated the relative levels of A-, B-, C-
RAF, and COT mRNAs in PTC and matched normal thyroid
tissues. Other drug resistance mechanisms, such as the splice
variants ofB-RAF,have not been investigated extensively inPTC
before treatment with novel targeted agents. We have, however,
performed a pilot study in 38 cases to determine the presence of
mutations in N-RAS (N-RASQ61) and MEK (exons 3 and 6),
which are reported to generate drug resistance in PTC. However,
no mutations could be detected (data not shown). In agreement
with these results, de novo drug resistance mechanisms should be
further investigated in future studies so that unnecessary treat-
ment can be avoided. Furthermore, the role of COT in tumor
biology should be focused on improving our understanding of the
mechanisms responsible for RAI-refractoriness.
In conclusion, RAF paralogues and COT expression levels
are higher in PTCs than in normal thyroid tissues. Aberrant
expression of COT correlates with both the BRAFV600E
mutation and tumor recurrence. Our data suggest that COT
will be an important molecular target for the treatment of RAI-
refractory B-RAFV600E-positive PTC and for the prediction of
tumor recurrence at initial diagnosis.
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